The Medical Letter on Drugs and Therapeutics
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the oral tyrosine kinase inhibitor neratinib (Nerlynx – Puma Biotechnology) for extended adjuvant treatment of adults with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant trastuzumab (Herceptin)-based therapy. HER2 is overexpressed in about 20% of breast cancers. Up to 30% of early-stage, HER2-positive breast cancer cases treated with trastuzumab-based adjuvant therapy recur.

MECHANISM OF ACTION — Neratinib binds irreversibly to HER2 and other enzymes that promote cell growth, resulting in reduced signaling, cell cycle arrest, and apoptosis.

CLINICAL STUDIES — In a double-blind trial (ExteNET), 2840 women with stage 1-3, HER2-positive breast cancer who had completed neoadjuvant and adjuvant trastuzumab-based therapy within the previous two years were randomized to receive oral neratinib 240 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Neratinib (Nerlynx) for HER2-Positive Breast Cancer
Article code: 1539d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian